ACHE and Alzheimer disease: In this observational study conducted in real life conditions, the treatment with Souvenaid for six months, alone or in combination with AChE inhi-bitors, was well tolerated and seemed to be associated to less cognitive impairment deterioration than the treatment only with AChE inhibitors or no treatment in patients with mild AD.